Jonathan McNeill insider trades: Crescent Biopharma (CBIO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jonathan reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | CBIO | ↓ Sell10b5-1 | 4,570 | $16.90 | $77K | Direct | Sep 18, 2026 (0d) |
| Jun 22, 2026 | CBIO | ↓ Sell10b5-1 | 20,549 | $17.99 | $370K | Direct | Jun 23, 2026 (1d) |
| Aug 19, 2024 | DYN | ↓ Sell | 2,705 | $45.12 | $122K | Direct | Aug 20, 2024 (1d) |
| Jun 11, 2024 | DYN | ↓ Sell | 1,823 | $31.34 | $57K | Direct | Jun 11, 2024 (0d) |
| May 16, 2024 | DYN | ↓ Sell10b5-1 | 2,774 | $28.27 | $78K | Direct | May 17, 2024 (1d) |
| Mar 11, 2024 | DYN | ↓ Sell10b5-1 | 109,601 | $26.11 | $2.9M | Direct | Mar 13, 2024 (2d) |
| Mar 7, 2024 | DYN | ↓ Sell10b5-1 | 2,434 | $25.85 | $63K | Direct | Mar 11, 2024 (4d) |
| Mar 1, 2024 | DYN | ↓ Sell | 28,528 | $28.46 | $812K | Direct | Mar 1, 2024 (0d) |
| Jan 26, 2024 | DYN | ↓ Sell | 20,000 | $24.53 | $491K | Direct | Jan 26, 2024 (0d) |
| Jan 4, 2024 | DYN | ↓ Sell | 31,900 | $16.59 | $529K | Direct | Jan 4, 2024 (0d) |
| Dec 11, 2023 | DYN | ↓ Sell10b5-1 | 1,245 | $10.72 | $13K | Direct | Dec 12, 2023 (1d) |
| Sep 18, 2023 | DYN | ↓ Sell10b5-1 | 1,261 | $9.41 | $12K | Direct | Sep 20, 2023 (2d) |
| Sep 12, 2023 | DYN | ↓ Sell | 1,266 | $10.41 | $13K | Direct | Sep 13, 2023 (1d) |
| Jun 13, 2023 | DYN | ↓ Sell10b5-1 | 2,259 | $12.68 | $29K | Direct | Jun 14, 2023 (1d) |
| Mar 14, 2023 | DYN | ↓ Sell10b5-1 | 2,209 | $13.18 | $29K | Direct | Mar 15, 2023 (1d) |
| Jan 18, 2023 | DYN | ↓ Sell | 10,000 | $14.03 | $140K | Direct | Jan 23, 2023 (5d) |
| Jan 9, 2023 | DYN | ↓ Sell | 30,150 | $11.57 | $349K | Direct | Jan 11, 2023 (2d) |
| Dec 12, 2022 | DYN | ↓ Sell10b5-1 | 472 | $10.87 | $5K | Direct | Dec 13, 2022 (1d) |
| Mar 11, 2022 | DYN | ↓ Sell10b5-1 | 481 | $8.73 | $4K | Direct | Mar 14, 2022 (3d) |
| Sep 21, 2021 | DYN | ↓ Sell10b5-1 | 1,274 | $15.90 | $20K | Direct | Sep 22, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CBIO insiders
Open-market trades in the last 12 months
About Jonathan McNeill's insider trades
Jonathan McNeill is President and COO at Crescent Biopharma (CBIO). Since Sep 21, 2021, Jonathan has reported no open-market purchases and 20 sales worth $6.1M on SEC Form 4. In the last 12 months: 2 sales ($447K).
12 sales (59% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (9 filings), option exercises (5 filings), shares returned to the company (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.